Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment.

ABSTRACT:

Background

Recent intravesical administration of adenoviral vectors, either as a single injection or in combination with immune checkpoint inhibitors, exemplified by cretostimogene grenadenorepvec and nadofaragene firadenovec, has demonstrated remarkable efficacy in clinical trials for non-muscle invasive bladder cancer. Despite their ability to induce an enhanced immune reaction within the lesion, the intracellular survival signaling of cancer cells has not been thoroughly addressed.

Methods

An analysis of the prognostic data revealed a high probability of therapeutic efficacy with simultaneous inhibition of mTOR and STAT3. Considering the challenges of limited pharmaco-accessibility to the bladder due to its pathophysiological structure and the partially undruggable nature

SUBMITTER: Lee DH 

PROVIDER: S-EPMC11184849 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature